Chinese | English

Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners

Linkedbio Report No.145

In this month summary, Lingmed recommends

  • China Deals summary 2016-2017
  • One Bio-similar asset recommendation
  • The September Financial analysis of global bio-pharmaceuticals market by Biotechgate data analysis team
Download the full report

Linkedbio Report No.144

CPA-McKinsey China Hospital Pharmaceuticals Report: An In-depth Perspective

  • China’s overall hospital pharmaceutical market reached around RMB734 billion in value in 2016. While year-on-year growth has continued to slow, it still grew at a healthy 11% in 2016
  • Class III hospitals account for 67% of total hospital pharmaceutical market sales, with a CAGR of 17% from 2011 to 2016, compared to 11% for the rest of the market
  • Tier 2 and 3 cities represent 60% of total sales and are growing fastest at 16% . In contrast, Tier 1 cities are growing at a slower rate of 10%
Download the full report

If you are interested in Lingmed historical reports,You may contact us by Tel: +86 21 5386 3003 or email

Confirm your details on form below to download this report

Company name *
Your name *
Email *
Phone *

©Copyright 2013 - 2017 Lingmed Limited